Clinical Trials Browser

Salivary Gland Neoplasms

NCT06502691 2026-03-02

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Phase 1/2 Recruiting

22 enrolled

Breast

Breast Neoplasms

NCT07268794 2025-12-08

CONVERT-HB1

Phase 2 Not yet recruiting

112 enrolled

Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04584008 2024-10-15

VISIONARY

Phase NA Active not recruiting

600 enrolled

EndocrineGastrointestinalNETSarcoma

Esophageal Squamous Cell Carcinoma, Biliary Tract Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Unknown Primary, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors

NCT06121557 2023-11-08

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Phase 1 Recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04724031 2023-03-14

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Unknown

150 enrolled

Gynecologic

Ovarian Neoplasms

NCT05406999 2022-08-16

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Phase 2 Recruiting

900 enrolled

Genitourinary

Neoadjuvant Therapy

NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Phase 2 Unknown

52 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed

200 enrolled

Tumor-Agnostic

Neoplasms

NCT05044091 2021-09-14

HOPEI

Unknown

100 enrolled

Gynecologic

Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms

NCT03951415 2021-04-01

DOMEC

Phase 2 Unknown

55 enrolled

Gynecologic

Uterine Neoplasms, Endometrial Neoplasms

NCT04326023 2021-03-11

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Completed

178 enrolled

Tumor-Agnostic

Neoplasms

NCT03227016 2021-01-27

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1 Unknown

30 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04582552 2021-01-20

ROMP

Unknown

60 enrolled

Gynecologic

Ovarian Neoplasms

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

Clinical Trials

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

CONVERT-HB1

VISIONARY

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

PD1 and PARP for Maintenance Therapy in NSLLC

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

HOPEI

DOMEC

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Study in Patients With SCLC of Veliparib in Combination With Topotecan

ROMP

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers